MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
25 Jun 2020
473
MedComm | Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Scimea

Though checkpoint immunotherapy has seemed to achieve much success in clinic application these days, a huge proportion of patients with RAS-driven tumors are still suffering from resistance to therapy and poor clinical outcomes. In this review, Antonio B. Ward et al reported the potential of RAS inhibitors to enhance or broaden the anticancer activity of currently available checkpoint immunotherapy.




1598430763(1).png


Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐driven oncogenesis also promotes immune evasion by increasing the expression of programmed cell death ligand‐1, reducing the expression of major histocompatibility complex molecules that present antigens to T‐lymphocytes and altering the expression of cytokines that promote the differentiation and accumulation of immune suppressive cell types such as myeloid‐derived suppressor cells, regulatory T‐cells, and cancer‐associated fibroblasts. Together, these changes lead to an immune suppressive tumor microenvironment that impedes T‐cell activation and infiltration and promotes the outgrowth and metastasis of tumor cells. As a result, despite the growing success of checkpoint immunotherapy, many patients with RAS‐driven tumors experience resistance to therapy and poor clinical outcomes. Therefore, RAS inhibitors in development have the potential to weaken cancer cell immune evasion and enhance the antitumor immune response to improve survival of patients with RAS‐driven cancers. This review highlights the potential of RAS inhibitors to enhance or broaden the anticancer activity of currently available checkpoint immunotherapy.

 


图片.pngFig. 1 Oncogenic RAS signaling increases tumor immune evasion.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.10

 

 


                                                                            

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.




SCIMEA Esophageal Disease Professional Committee Officially Established
Internal training of the association| new media status quo and thinking mode
Internal Training | On Professional Behavior
Special Program of Medical Approach丨 Panda Dentist Series Cartoon Books Published for Online Popular Science and Oral Healthcare for Children
Oncology Multidisciplinary Treatment (MDT) Professional Committee Officially Founded under Sichuan International Medical Exchange & Promotion Association
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1